Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAN-TU prevention study in dominantly inherited Alzheimer's disease
NL-OMON60157Phase 3Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of remternetug in Alzheimer's disease (AD) (3 arms), sponsored by Washington University School of Medicine. Planned start Aug 2025; status: withdrawn.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON60157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60157.